Should I Buy TYRA? TYRA 2026 Analysis

Should You Buy Tyra Biosciences Inc (TYRA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

31.000

1 Day change

5.23%

52 Week Range

32.440

Analysis Updated At

2026/01/30

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now. TYRA is holding a broader uptrend (bullish moving-average stack) and is sitting just above a key pivot/support area (~30.11) after a sharp regular-session drop (-4.7%) that was partially retraced post-market (+3.0%). With no negative news this week and a strong, improving Wall Street stance (multiple Overweight/Outperform calls with large upside to targets), the current ~30.8 area looks like an attractive entry for an impatient buyer looking for near-term rebound potential toward the 32–33 resistance zone and positioning into 2026 clinical catalysts.

Technical Analysis

Trend/price action: Primary trend still bullish given SMA_5 > SMA_20 > SMA_200, suggesting the medium/long-term structure is intact despite today’s volatility. Momentum: MACD histogram is negative (-0.0675) and expanding lower, signaling near-term momentum has weakened and price may chop/consolidate before the next push. RSI: RSI_6 at ~54.5 is neutral—no overbought condition, leaving room for a rebound if buyers step in. Key levels: Pivot/support ~30.107 (price ~30.82 is above it). If strength continues, first upside levels are R1 ~32.032 then R2 ~33.221. Downside supports to watch are S1 ~28.181 then S2 ~26.992. Pattern-based forward odds: Similar-candlestick stats imply ~+1.74% over 1 week and ~+9.9% over 1 month, supporting a buy-for-rebound posture.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Options sentiment: Open-interest put/call ratio of 0.07 is extremely call-heavy (bullish positioning/expectations). However, today’s option volume put/call ratio is 3.0, indicating the small amount of flow that did trade skewed to puts (possible short-term hedging after the down day). Volatility: 30D IV ~135.6 vs historical vol ~51.3 (options are pricing substantial event/biotech risk). IV percentile ~20 and IV rank ~27 suggest IV is lower than it has often been historically for TYRA, despite being high in absolute terms. Activity: Very low absolute volume (todays volume 4) limits how much weight to place on the daily put-skew; OI remains decisively call-tilted.

Technical Summary

Sell

Buy

Positive Catalysts

after a sharp drop, creating a plausible near-term rebound setup toward 32–
Upcoming earnings date set: QDEC 2025 earnings on 2026-02-11 (after hours) can act as a positioning catalyst.

Neutral/Negative Catalysts

Near-term momentum deterioration: MACD histogram is negative and weakening, consistent with potential short-term consolidation.
Business stage: Financials show no revenue (clinical-stage profile), so the stock remains heavily catalyst-driven.
Event sensitivity: Options imply very high expected volatility (30D IV ~135.6), meaning price can move aggressively around catalysts/updates.
Flow nuance: Despite call-heavy open interest, today’s option volume skewed to puts (3.0 put/call), which can reflect near-term caution/hedging after the selloff.
No supportive near-term news: No fresh positive headline flow in the last week to immediately reverse sentiment.

Financial Performance

Latest quarter: 2025/Q3. Revenue: 0 (no change YoY; still pre-commercial). Loss trend: Net income improved to -$29.868M (loss narrowed ~~24.37% YoY) and EPS improved to -0.50 (~~21.95% YoY improvement). This shows better cost control versus prior year, but the company remains in investment/clinical execution mode rather than revenue-driven growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Ratings/targets have moved more bullish with higher targets and fresh coverage.

2026-01-27: Barclays initiated Overweight, PT $59.
2026-01-23: Piper Sandler reiterated Overweight, raised PT to $42 from $33.
2025-12-16: Wedbush reiterated Outperform, raised PT to $37 from $30; added to Best Ideas.
2025-12-04: Goldman Sachs initiated Early-Stage Biotech. Wall Street pros view (bull case): Dabogratinib framed as potentially best-in-class with multiple high-value indications; approaching key de-risking Phase 2 catalysts; perceived biotech-sector tailwinds into 2026. Wall Street cons view (bear case, implied): Early-stage/clinical execution risk and catalyst dependence with no current revenue base. Influential/political trading: No recent congress trading data available; hedge fund and insider trends listed as neutral with no significant recent activity.

5 Analyst Rating

Wall Street analysts forecast TYRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TYRA is 33.75 USD with a low forecast of 30 USD and a high forecast of 37 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 29.460

Low

Averages

33.75

High

Current: 29.460

Low

Averages

33.75

High

Oppenheimer

Outperform

maintain

$36 -> $50

AI Analysis

2026-02-03

Reason

Oppenheimer

Price Target

$36 -> $50

AI Analysis

2026-02-03

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Tyra Biosciences to $50 from $36 and keeps an Outperform rating on the shares. The firm met with management last week in San Diego, CA. Oppenheimer notes shares are now at an all-time high. Part of that momentum, in its view, reflects a consummation of the "no news is good news trade." The other part is "just plain old good messaging," as management has done a good job conveying that this is a $10B-plus market opportunity across bladder cancer and bone growth disorders.

Barclays

Overweight

initiated

$59

2026-01-27

Reason

Barclays

Price Target

$59

2026-01-27

initiated

Overweight

Reason

Barclays initiated coverage of Tyra Biosciences with an Overweight rating and $59 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TYRA

Unlock Now

TYRA Should I Buy

TYRA Should I Buy

Should You Buy Tyra Biosciences Inc (TYRA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch